Skip to content

Study · Randomized controlled trial · n = 197 · 2021

3 results

Intranasal oxytocin, testosterone reactivity, and human competitiveness.

Cherki BR, Winter E, Mankuta D, Israel S

Psychoneuroendocrinology9 Jul 2021Cited by 6 (Europe PMC)

PMID34298279 (opens in a new tab)DOI10.1016/j.psyneuen.2021.105352 (opens in a new tab)PepBankPUB-34298279
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    The interaction of oxytocin, testosterone reactivity and sex on willingness to compete stayed significant after controlling for performance, self-confidence and risk-aversion.

    In plain wordsThe way oxytocin, testosterone changes and sex combined to affect willingness to compete held after accounting for performance, confidence and risk-aversion.

    Peptide
    Oxytocin
    Outcome
    MixedThree-way interaction of oxytocin, T-reactivity and sex on competitiveness
    Study

    n = 197

    Comparator
    Placebo
    Outcome group
    Social behavior and cognition · Mental health and mood
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    The interaction between OT, T-reactivity, and sex on competitive preferences remained significant even after controlling for potential mediators such as performance, self-confidence, and risk-aversion, suggesting that this three-way interaction effect was specific to competitive motivation rather th…
    1 context sentence
    Summary · context
    In a double-blind placebo-control design, 204 subjects (102 females) self-administrated OT or placebo
  2. 02HumanRandomized controlled trialEfficacy outcome

    In females, testosterone reactivity during competition was not associated with willingness to compete under either oxytocin or placebo.

    In plain wordsIn women, changes in testosterone during competition were not linked to willingness to compete, with oxytocin or placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeT-reactivity and competitiveness association in females
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Social behavior and cognition · Mental health and mood
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    Under both OT and placebo, T-reactivity during competition was not associated with competitiveness in females.
    1 context sentence
    Summary · context
    In a double-blind placebo-control design, 204 subjects (102 females) self-administrated OT or placebo
  3. 03HumanRandomized controlled trialEfficacy outcome

    In males, the association between testosterone reactivity and willingness to compete depended on oxytocin: positive under placebo, absent under oxytocin.

    In plain wordsIn men, a link between testosterone changes and willingness to compete appeared with placebo but not with oxytocin.

    Peptide
    Oxytocin
    Outcome
    MixedT-reactivity and competitiveness association in males
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Social behavior and cognition · Mental health and mood
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    However, in males, the association between T-reactivity and competitiveness was OT-dependent. That is, males under placebo demonstrated a positive correlation between T-reactivity and the willingness to engage in competition, while no association was observed in males receiving OT.
    1 context sentence
    Summary · context
    In a double-blind placebo-control design, 204 subjects (102 females) self-administrated OT or placebo

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.